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Introduction: This prospective randomized study aimed to evaluate the role of WBRT + SRS compared to SRS alone
and to WBRT alone in improvement of overall survival, brain local control and neurologic manifestations.
Patients and methods: The trial included 60 patients with 1 to 3 brain metastases treated at the Radiotherapy
Department, National Cancer Institute. 21 patients received WBRT + SRS, 18 patients received SRS alone and 21
patients received WBRT alone.
Results: Median local control was significantly better for WBRT + SRS compared to SRS alone & WBRT alone (10 vs 6
vs 5 months, respectively, P = 0.04). There was non significant survival benefit for WBRT + SRS compared to SRS
alone & WBRT alone. Survival was significantly better for patients with controlled primary tumor who received
WBRT + SRS compared to SRS alone & WBRT alone (median survival was 12 vs 5.5 vs 8 months, respectively.
P = 0.027). Regardless of the treatment group, median survival and median local control were highly significantly better
for single brain site involvement compared to multiple brain sites involvement (P = 0.003 & P = 0.001, respectively), and
median brain local control was significantly better for single lesion compared to multiple lesions (P = 0.05).
Conclusions: WBRT + SRS is an effective, safe tool in treatment of patients with 1 to 3 brain metastses improving the
brain local control, but further studies with larger number of patients is recommended.
Keywords: Whole brain irradiation, Stereotaxy, Radiotherapy, Brain metastasesIntroduction
Brain metastases are the most common intracranial tu-
mors in adults, accounting for more than one-half of
brain tumors. In patients with systemic malignancies,
brain metastases occur in 10%-30% of adults and 6%-
10% of children [1-3]. The incidence of brain metastases
appears to be rising as a result of superior imaging mo-
dalities and earlier detection [4].
The most common route of metastatic dissemination
resulting in brain metastases is hematogenous, and it is
therefore presumed that the entire brain is “seeded” with
micrometastatic disease, even when only a single intra-
cranial lesion is detected [5]. Recently, this assumption
has been questioned, prompting a contrarian philosophy* Correspondence: hoda_elbakry@yahoo.com; m_mahmoud1973@hotmail.
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article, unless otherwise stated.that in some patients, the intracranial disease is truly
limited—the so-called oligometastases situation [5].
The management of brain metastases can be divided
into symptomatic and therapeutic strategies. Symptoma-
tic therapy often includes corticosteroids to reduce peri-
tumoral edema and anticonvulsants to prevent recurrent
seizures. Therapeutic approaches to brain metastases
include surgery, whole brain radiotherapy (WBRT), ste-
reotactic radiosurgery (SRS), and chemotherapy. Many
patients are treated with a combination of these, and
treatment decisions must take into account factors such
as patient age, functional status, primary tumor type, ex-
tent of extracranial disease, prior therapies, and number
of intracranial lesions [4].
WBRT has been used for decades as the mainstay of
the management of patients with brain metastases being
widely applicable and technically easy to deliver. It also
improves symptoms in 75% of symptomatic patientstral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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3–6 months compared with a median survival of only
1–2 months in untreated patients [6,7].
However, for patients who truly have limited intracra-
nial disease, the potential exists that WBRT could be re-
placed by focal therapeutic options such as resection or
SRS [5].
Also, the recognition of potential late neurotoxicity
and the inadequate local control with WBRT and the de-
velopment of better imaging and focal therapies, such as
microsurgical resection and SRS, have shifted the re-
search focus to study which patients are best treated
with WBRT and which patients are best treated with
other therapies. Numerous randomized trials have inves-
tigated strategies for patients who would most likely
benefit from these aggressive therapies, namely those of
good performance status with single or few brain metas-
tases. The median survival times reported for these rela-
tively favourable prognosis patients enrolled in these
trials were typically 6–11 months [8].
SRS employs multiple convergent beams to deliver a
single, large dose of radiation to a discrete target vol-
ume. The three most common delivery systems are the
linear accelerator, gamma knife, and cyclotron, which
make use of high-energy photons, gamma rays, and pro-
tons, respectively. Most brain metastases have distinct
radiographic and pathologic margins, making them at-
tractive targets for SRS [4]. SRS has emerged as a com-
mon treatment modality for newly diagnosed patients,
alone or in combination with WBRT, and as salvage
therapy for progressive intracranial disease after WBRT.
Aim of the study
The current study is a prospective randomized study to
evaluate role of WBRT combined with SRS compared to
SRS alone and to WBRT alone in improvement of the
overall survival, brain local control, performance status
and its effect on treatment-related morbidity.
Patients and methods
The present work involved 60 patients with 1 to 3 brain
metastases, each with a maximum diameter of no more
than 4 cm on contrast-enhanced MRI scans, derived
from a histologically confirmed systemic cancer. An eth-
ical approval and an informed written consent was ob-
tained from the patients before entering the study. This
study was approved by the ethical committee of National
Cancer Institute Cairo University Egypt.
These patients are randomized into 3 arms, 21 patients
received whole brain radiotherapy WBRT, 18 patients
received SRS and 21 patients received WBRT + SRS,
the study took place in the radiotherapy department,
National Cancer Institute, Cairo University, Egypt from
January 2008 until March 2011 with the following inclusioncriteria: Age ≤ 70 years, KPS ≥ 70%, Ensured adequate or-
gan function (Haemogram, Kidney and Liver function), no
previous treatment for brain metastases.
Regarding technique of treatment
1) Patient immobilization
Head and neck immobilization for patients of
WBRT group was performed using thermoplastic
mask and head support in supine position.
Precise immobilization of patients of the SRS group
was done by the Brown-Roberts-Wells CT
Stereotactic (BRW) localization system frame. Local
anaesthesia (1 cc of 0.5% xylocaine) was injected
subcutaneously at the site of insertion of each
headpins; the pins are artifact free carbon fiber with
ceramic tips as shown in Figure 1.
2) Image acquisition (CT- MRI- Fusion)
The MRI study consists of post-contrast
T1-weighted images, followed by the acquisition
T2-weighted and FLAIR images. Slice thickness was
2.5 mm with no gaps.
For patients receiving SRS; a Brown-Roberts-Wells
CT stereotactic (BRW) frame and localizer system
were used and attached to the CT couch, using an
adjustable support bracket. CT scan was taken
throughout the full cranial volume from the superior
edge of the frame to the cranial vertex after injection
of intra venous contrast. The image slice interval
was 2.5 mm. The patient’s images were transferred
to the treatment planning computer using the
transfer protocol and optical disc.
Axial MRI images were fused to the axial CT images
using chamfer match technique where sets of points
belonging to the same anatomical structures on each
study were used.
3) Target and critical organs deleneation
The stereotactic team began by delineating on each
image slice the external cranial surface, dose limiting
structures such as optic nerves and chiasma, eyes,
functional brain areas such as the brainstem and the
target volume which included the gross target
volume +1 mm as planning target volume. In
addition, all nine rod intersections on each slice are
digitized to define the transformation for each slice
from the CT reference system to the frame system.
4) Selection of method of treatment
The most important criteria for selection of SRS
method were tumor volume and shape. Patients
with radiographically well defined lesion with
small volume were candidate for SRS using non
coplanar arcs by circular collimator (cones). In
general, arc therapy was preferred in tumors with
rounded regular surface, while lesions with large
Figure 1 Distribution of patients in studied arms according to no. of brain lesions.
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mMLC.
5) Evaluation of the treatment plans
Multiple parameters were evaluated including
surface dose, isodose distribution, dose volume
histogram, conformity index and tissue volume ratio.
6) Quality assurance
To confirm the precision of isocenter, as SRS
treatment uses the rotation of gantry and couch.
Mechanical Isocenter Standard (MIS; Radionics
Inc.), Rectilinear Phantom Pointer (RLPP;
Radionics Inc.) were used to achieve this
precision.
7) Dose specification and fractionation
The WBRT dosage schedule is 30 Gy in 10 fractions
over 2 weeks delivered using megavoltage machines
with photon beams of energy 6 MV. Treatments
were delivered through parallel opposed fields that
cover the entire cranial contents. Doses were
specified at the central axis at midplane on the
brain.
The WBRT treatment preceded SRS when patients
were assigned to the WBRT + SRS group and the
whole treatment duration was within 1 month.
In the current study, the prescribed dose of SRS in
the WBRT + SRS arm ranged from 14 to 20 Gy
(mean = 14.6 Gy, median = 14 Gy), while the
prescribed dose in the SRS alone arm ranged from
18 to 20 Gy (mean = 19.5 Gy, median dose = 20 Gy).
The dose choice was dependant on the size, number
of the brain lesion and proximity to critical
structures.Regarding patient follow-up
The follow-up included neurologic examinations and mag-
netic resonance imaging 3 months after start of treatment
and in 3 months intervals to evaluate response or failure
criteria and to evaluate treatment morbidity.Statistical methods
This was an intention to treat analysis.
Comparison between two groups for numerical vari-
ables was done using either student t- test or Mann–
Whitney –U test (non-parametric t-test) as appropriate.
Comparison between more than two groups for numer-
ical variables was done using ANOVA or non parametric
Kruskal-Wallis as appropriate. Relation between qualita-
tive data was done using Chi-square test or non- paramet-
ric Fisher’s exact test as appropriate. Survival analysis was
done using Kaplan-Meier curve with log rank for com-
parison between different arms.Results
The present work included 60 patients with brain metas-
tases divided into 3 arms; 21 patients received WBRT +
SRS, 21 patients received WBRT and 18 patients received
SRS. The mean follow up duration was 10 months and
the median follow up duration was 8.5 months (range
0–34 months).
All the thirty nine patients who received SRS were
treated with Brown-Roberts-Wells CT stereotactic (BRW)
localization system frame.
The mean prescribed isodose line was 89% (ranged from
85% to 93%). All lesions were treated with prescription
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per our protocol (ranged from 1 to 1.5, mean = 1.3).
Twenty six patients (66.7%) were treated using non co-
planar arcs by the cone, with a diameter ranging from
1.25 to 4 cm; the remaining thirteen patients (33.3%)
were treated using the mMLC. The number of beams
used ranged from 5 to 7 beams with a mean of 6 beams.
Number of brain lesions
The majority of patients had single metastasis 70% of pa-
tients (42/60) with 15 (71.4%), 13 (62%) and 14 (77.8%) in
WBRT + SRS, WBRT & SRS arms, respectively, 23.3% of
patients had two lesions (14/60) with 5 (23.8%), 5 (23.8%)
and 4 (22.2%) in WBRT + SRS, WBRT & SRS arms, re-
spectively while 6.7% of patients (4/60) had three lesions
with 1 (4.8%), 3 (14.2%) and 0 (0%) in WBRT + SRS,
WBRT & SRS arms, respectively. The total no. of treated
brain lesions was 82 with 28 lesions in WBRT + SRS arm,
32 lesions in the WBRT arm and 22 lesions in the
SRS arm.
Largest brain lesion size
Brain lesion(s) with maximum dimensions larger than
or equal 3 cm were found in 50% of patients (30/60)
with 9 patients (42.8%), 16 patients (76.2%) and 5 pa-
tients (28%) in the WBRT + SRS, WBRT & SRS arms,
respectively.
Sites of the brain lesions
Lobar lesions were the most common and were found in
68/82 lesions (82.9%) followed by cerebellar lesions (14/82
lesions i.e., 17.1%).
According to number of brain sites involved; 46 pa-
tients (76.7%) had only one site involved (e.g. unilateral
parietal lobe, frontal lobe, occipital lobe, temporal lobe,
cerebellum), while 14 patients (23.3%) had more than
one site involved. Regarding the three treatment arms;
17 patients (80%), 14 patients (67%) and 15 patients
(83.3%) had one brain site involved in WBRT + SRS,
WBRT & SRS arms, respectively.
Definition of response
The bidimensional product for each of the brain metas-
tases identified at baseline was measured and calculated.
The bidimensional product is defined as the largest di-
mension multiplied by the second largest dimension that
is perpendicular to it. This value was recorded on the
baseline form and every subsequent follow-up form and
the response was recorded as whether there is CR or PR
or no response or CNS progression. The appearance
(yes/no) of any new brain metastases was recorded on
all follow-up forms. Local control was defined as un-
changed or improved serial post-treatment MRI scansjudged as either complete response, partial response, or
stable disease.
– Complete response (CR) - disappearance of all
tumors on consecutive CT or MRI scans at least
one month apart, off steroids, and neurologically
stable or improved.
– Partial response (PR) - 50% or greater decrease in
tumor size on consecutive CT or MRI scans at least
one month apart, steroid dose stable or reduced,
and neurologically stable or improved.
– Stable disease - a 0-50% decrease in size of all
lesions with improving or stable neurological
examination.
– CNS progression - was defined as a defined
increase in perpendicular bi-dimensional tumor area
for any of the 1–3 tracked brain metastases, or the
appearance of any new brain metastasis on a
follow-up MRI.
For lesions smaller than 1 cm in maximum diam-
eter, a maximum increase of 50% in perpendicular bi-
dimensional treatment area was necessary to score as
progression. This caveat was included to account for
potential variability in measurement, which was most
susceptible to proportionate errors at smaller sizes. For
greater than 1 cm lesions, the definition was a 25% rule
for change.
Rates of response
Review showed non-significant higher response rates at
3 months in the WBRT + SRS group 71.5% of lesions vs
34.4% of lesions in the WBRT arm vs 45.4% of lesions in
the SRS arm (P = 0.49).
Local control analysis
The best local control (LC) of the treated patients at
1 year was reported in the WBRT + SRS group 9/21
(42.9%) vs 4/21 (19%) for WBRT group and 4/18 (22.2%)
for SRS group with statistically significant P value = 0.04
as shown in Figure 2.
As regards number of brain lesions (that is to say the
total number of brain lesions regardless their anatomical
site) and its effect on LC duration; Figure 3 shows sig-
nificantly better 6 months LC and 1 year LC duration
were reported for patients with single lesion (61.9% and
33.3% respectively) compared to those with multiple le-
sions (39% and 16.6% respectively) with statistically sig-
nificant P value = 0.05.
As regard number of sites of brain lesions; (that is to
say the anatomical sites of the brain involved by lesions
regardless their number) significantly better 6 months
LC and 1 year LC duration were reported for patients
with lesions in one brain site (65% and 34.7 respectively)
Figure 2 Local control of the 3 treatments groups.
Figure 3 The LC according to number of brain lesions.
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(21.5% and 7.1% respectively) with statistically significant
P value = 0.001 as shown in Figure 4.
Subgroup analysis indicated that WBRT plus SRS pro-
vided LC benefit to patients with brain metastasis of less
than 3 cm maximum dimension (median LC was 12 vs 3
vs 6 months for WBRT + SRS vs WBRT vs SRS, respect-
ively) with statistically significant P value = 0.004.
Survival analysis
Figure 5 shows the median survival time for all patients
was 8.5 month. Overall survival at 6 month was 61.6%
and at 12 month was 30%. While Figure 6 shows overall
survival according to the treatment groups.
As regard number of sites of brain lesions; significantly
better 6 months, 1 year were reported for patients with
lesions in one brain site (69.5%, 37% respectively) com-
pared to those with lesions in multiple brain sites (35.7%
and 7.1% respectively) (P = 0.003) as shown in Figure 7.
Subgroup analysis indicated that WBRT plus SRS pro-
vided survival benefit to patients whose largest brain
metastasis was 3 cm in diameter (median survival was
15 months vs 8 months vs 5 months for WBRT + SRS vs
SRS vs WBRT, respectively with statistically significant
P value = 0.002), also subgroup analysis showed that
patients with controlled primary who recieved WBRTFigure 4 The LC according to number of brain sites involved.plus SRS had survival benefit compared to SRS vs
WBRT (median survival was 12 months vs 8 months
vs 5.5 months for WBRT + SRS vs SRS vs WBRT, respect-
ively with statistically significant P value = 0.027).
Overall survival was compared with different prog-
nostic factors such as treatment modality recieved, num-
ber of lesions , if any previous chemotherapy was given
and the RPA but all these correlations were statistically
insignificant.
Treatment related toxicity
Acute toxicities were identified as events that arose within
90 days from start of radiotherapy and late toxicities as
events that occurred 3 months after start of radiotherapy
and thereafter. Acute and late toxicities did not differ
greatly between treatment groups [Tables 1 and 2].
The total number of patients was less than the cal-
culated total as some patients had multiple compli-
cations. Grading is according to the National Cancer
Institute’s Common Toxicity Criteria version 2.0 (Trotti
et al., 2000).
The total number of patients was less than the cal-
culated total as some patients had multiple complica-
tions. Neurologic worsening is classified according to the
RTOG/EORTC late radiation morbidity scoring schema
(RTOG, 1999).
Figure 5 Overall survival for all patients.
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Regarding local control
The current study reported improvement in local con-
trol in patients treated with WBRT + SRS as compared
to WBRT alone and to SRS alone, where the median
local control was 10 months for WBRT + SRS compared
to 6 months and 5 months for SRS alone and WBRT
alone, respectively (P = 0.048).
These results are similar to Kondziolka et al., Chougule
et al. and Andrews et al., these three randomized trialsFigure 6 Overall survival for each treatment group.that detected an improvement in local brain control in pa-
tients treated with WBRT + SRS as compared with WBRT
alone [9-11]. Also these results are similar to the results of
Aoyama et al., Chougule et al., Chang et al. and Kocher
et al. [12]. These four randomized trials that detected an
improvement in local brain control in patients treated with
WBRT + SRS as compared with SRS alone [5,10,13,14].
As regard response rate; MRI assessment showed higher
response rates of brain lesions at 3 months follow up for
WBRT + SRS (71.5%) compared to 45.4% and 34.4% for
Figure 7 Overall survival according to number of brain sites involved.
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result is similar to that of the RTOG-9508 trial which re-
vealed higher response rate at 3 months follow-up for
WBRT + SRS compared to WBRT alone after assessing
153 MRI sets out of 270 MRI sets for 270 surviving pa-
tients (P = 0.043) [11].
Regarding overall survival
The current study revealed no significant difference in
6-month, 12-month and median survival between the
three treatment arms.
These results are similar to Kondziolktout et al.,
Chougule et al. and Andrews et al., were these three
randomized trials reported non statistically significant
improvement in overall survival with the use of WBRT
and SRS boost as compared with WBRT alone [9-11].Table 1 Number of patients suffering from treatment-
related acute toxicity
WBRT + SRS WBRT SRS
> Grade 2 headache 2 2 2
> Grade 2 vomiting 0 0 1




Seizures 0 0 1 (grade 2
seizures)
Total 3 (14%) 3 (14%) 2 (11%)In the current study analysis of the different prog-
nostic factors that might affect the overall survival in
current study were done; the current study reported a
highly significant better 6 months, 1 year survival & me-
dian survival duration for patients with lesions in one
brain site compared to those with lesions in multiple
brain sites (P = 0.003).
Subgroup survival analyses of the RTOG-9508 trial re-
vealed a survival advantage in the WBRT + SRS group
for patients with a single brain metastasis (p = 0.039),
also there were trends towards better survival with SRS
boost in patients with largest tumor > 2 cm, favourable
histology, KPS ≥90 & RPA class 1 patients [11].
Regarding SRS doses
The prescribed doses in the WBRT + SRS arm in our
study were less than those prescribed in the RTOG-9508
trial which treated metastases ≤ 2 cm in maximum dia-
meter with a dose of 24 Gy; metastases > 2 cm to 3 cmTable 2 Number of patients suffering from treatment-
related late toxicity
WBRT + SRS WBRT SRS
Radionecrosis 1 0 1




Total 3 (14%) 2 (9%) 2 (11%)
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[11], this was due to several reasons:
(a) The lack of sufficient of experience regarding SRS
in our department being a new technique for us
with fear of increased complications with higher
doses.
(b) Our doses were in line with those used in the
JROSG 99–1 trial which treated metastases with a
maximum diameter of ≤ 2 cm with 22 to 25 Gy and
those with 2–3 cm with 18 to 20 Gy in the SRS
alone arm. These doses were reduced by 30% when
the treatment was combined with WBRT. The
JROSG 99–1 trial reported that these choices of
doses were due to “our preexisting experience of
SRS with a 30% reduced SRS dose combined with
WBRT indicated that there is not a significant
difference in local tumor control (data not shown)
compared with SRS with the dose suggested in the
RTOG protocol” [5].
(c) The RTOG-9508 trial reported “no survival
advantage was noted between groups when
assessing dose delivered” and also “higher isodose
prescriptions did not affect local control rates in the
radiosurgery boost arm” [11].
Conclusions
In conclusion, our data suggest that WBRT + SRS is an
effective, safe tool in treatment of patients with 1 to 3
brain metastases improving the local control compared
to WBRT alone and SRS alone especially for patients
with brain metastasis of less than 3 cm maximum di-
mension and with acceptable tolerance especially regard-
ing neurological toxicity. Also WBRT + SRS provide better
survival in patients whose largest brain metastasis was less
3 cm in diameter and those with controlled primary. Re-
gardless of the treatment group, our data suggest that
both survival and local control are better for single brain
site involvement compared to multiple brain sites involve-
ment. Further studies with larger number of patients
is needed to be conducted for more reliable statistical
results.
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